Document Detail

Novel histone deacetylase inhibitor CG200745 induces clonogenic cell death by modulating acetylation of p53 in cancer cells.
MedLine Citation:
PMID:  20978925     Owner:  NLM     Status:  In-Data-Review    
Histone deacetylase (HDAC) plays an important role in cancer onset and progression. Therefore, inhibition of HDAC offers potential as an effective cancer treatment regimen. CG200745, (E)-N(1)-(3-(dimethylamino)propyl)-N(8)-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide, is a novel HDAC inhibitor presently undergoing a phase I clinical trial. Enhancement of p53 acetylation by HDAC inhibitors induces cell cycle arrest, differentiation, and apoptosis in cancer cells. The purpose of the present study was to investigate the role of p53 acetylation in the cancer cell death caused by CG200745. CG200745-induced clonogenic cell death was 2-fold greater in RKO cells expressing wild-type p53 than in p53-deficient RC10.1 cells. CG200745 treatment was also cytotoxic to PC-3 human prostate cancer cells, which express wild-type p53. CG200745 increased acetylation of p53 lysine residues K320, K373, and K382. CG200745 induced the accumulation of p53, promoted p53-dependent transactivation, and enhanced the expression of MDM2 and p21(Waf1/Cip1) proteins, which are encoded by p53 target genes. An examination of CG200745 effects on p53 acetylation using cells transfected with various p53 mutants showed that cells expressing p53 K382R mutants were significantly resistant to CG200745-induced clonogenic cell death compared with wild-type p53 cells. Moreover, p53 transactivation in response to CG200745 was suppressed in all cells carrying mutant forms of p53, especially K382R. Taken together, these results suggest that acetylation of p53 at K382 plays an important role in CG200745-induced p53 transactivation and clonogenic cell death.
Eun-Taex Oh; Moon-Taek Park; Bo-Hwa Choi; Seonggu Ro; Eun-Kyung Choi; Seong-Yun Jeong; Heon Joo Park
Related Documents :
11369765 - Activation of a p53-independent, sphingolipid-mediated cytolytic pathway in p53-negativ...
10846825 - Prognostic and predictive significance of p53 mutation in aggressive b-cell lymphoma.
19564615 - Inhibition of serine/threonine phosphatase pp2a enhances cancer chemotherapy by blockin...
9374435 - Influence of ionizing radiation on proliferation, c-myc expression and the induction of...
4550675 - Interaction of maltose transport with the transport of glucose and galactosides.
1631495 - Binding of epidermal growth factor to receptors in preparations of enriched porcine par...
Publication Detail:
Type:  Journal Article     Date:  2010-10-27
Journal Detail:
Title:  Investigational new drugs     Volume:  30     ISSN:  1573-0646     ISO Abbreviation:  Invest New Drugs     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-02-13     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8309330     Medline TA:  Invest New Drugs     Country:  United States    
Other Details:
Languages:  eng     Pagination:  435-42     Citation Subset:  IM    
Department of Microbiology, Center for Advanced Medical Education by BK21 Project, College of Medicine, Inha University, Jungsuck B/D B-Dong 3F, 7-241, 3rd Street, Shinheung-Dong, Jung-Gu, Inchoen, 400-712, South Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A phase I study of temsirolimus and metformin in advanced solid tumours.
Next Document:  Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886).